103909-78-0

Basic information

• Product Name: 4-{(S)-1-[(1S,3R,9S,10R,13S,14R)-1,3-Bis-(tert-butyl-dimethyl-silanyloxy)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-ethoxy}-2-methyl-butan-2-ol
• Synonyms: 4-{(S)-1-[(1S,3R,9S,10R,13S,14R)-1,3-Bis-(tert-butyl-dimethyl-silanyloxy)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-ethoxy}-2-methyl-butan-2-ol
• CAS NO: 103909-78-0
• Molecular Weight: 647.142
• Mol File: 103909-78-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-{(S)-1-[(1S,3R,9S,10R,13S,14R)-1,3-Bis-(tert-butyl-dimethyl-silanyloxy)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-ethoxy}-2-methyl-butan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{(S)-1-[(1S,3R,9S,10R,13S,14R)-1,3-Bis-(tert-butyl-dimethyl-silanyloxy)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-ethoxy}-2-methyl-butan-2-ol(103909-78-0)
• EPA Substance Registry System: 4-{(S)-1-[(1S,3R,9S,10R,13S,14R)-1,3-Bis-(tert-butyl-dimethyl-silanyloxy)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-ethoxy}-2-methyl-butan-2-ol(103909-78-0)

Safety Data

• Hazardous Substances Data: 103909-78-0(Hazardous Substances Data)

Upstream product

• 20998-18-9 1α,3β-dihydroxy-androst-5-en-17-one 

Downstream Products

• 142785-61-3 1α,3β-dihydroxy-20(S)-(3-hydroxy-3-methylbutyloxy)pregna-5,7-diene 
• 143773-33-5 (5Z,7E)-(1S,3R)-1,25-dihydroxy-22-oxa-9,10-secocholesta-5,7,10⁽¹⁹⁾-trien-3-yl (2',2',2'-trichloroethylglutarate) 
• 143773-34-6 (5Z,7E)-(1S,3R)-1,25-dihydroxy-22-oxa-9,10-secocholesta-5,7,10⁽¹⁹⁾-trien-3-yl hemiglutarate 
• 103909-75-7 maxacalcitol 
• 103909-75-7 1α,25-dihydroxy-22-oxavitamin D₃ 

Relevant articles and documents

Industrial synthesis of maxacalcitol, the antihyperparathyroidism and antipsoriatic vitamin D3 analogue exhibiting low calcemic activity

Maxacalcitol, the 22-oxa-derivative of 1α,25-dihydroxyvitamin D 3 and used currently as an antihyperparathyroidism and antipsoriatic drug, has been synthesized in seven chemical steps from 1α- hydroxydehydroepiandrosterone on the basis of our previously developed route. The present synthesis allows the production of the protected form of the penultimate intermediate in 26% overall yield in a kilogram scale reaction employing neither difficult reaction conditions nor chromatographic purification, having overcome all the difficulties involved in the previous route.